Accuracy of line probe assays for the diagnosis of pulmonary and multidrug-resistant tuberculosis: A systematic review and meta-analysis

European Respiratory Journal

Volumn 49, Issue 1, 2017, Pages

  Nathavitharana, Ruvandhi R ^a   Cudahy, Patrick G T ^b   Schumacher, Samuel G ^c   Steingart, Karen R ^d   Pai, Madhukar ^e   Denkinger, Claudia M ^a,c  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c FIND   (Switzerland)

^d LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

^e MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ISONIAZID; RIFAMPICIN; TUBERCULOSTATIC AGENT;

BACTERIAL GENE; BACTERIUM CULTURE; BACTERIUM DETECTION; BIOASSAY; CLINICAL PRACTICE; COMPOSITE REFERENCE STANDARD; DATA EXTRACTION; DIAGNOSTIC ACCURACY; FALSE POSITIVE RESULT; GENE MUTATION; HUMAN; KATG GENE; LINE PROBE ASSAY; LUNG TUBERCULOSIS; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; PHENOTYPIC REFERENCE STANDARD; PRIORITY JOURNAL; QUALITY CONTROL; REVIEW; RPOB GENE; SENSITIVITY ANALYSIS; SENSITIVITY AND SPECIFICITY; SEQUENCE ANALYSIS; SMEAR; SMEAR GRADE; STANDARD; STUDY DESIGN; SYSTEMATIC REVIEW; DNA PROBE; DRUG EFFECTS; GENETICS; META ANALYSIS; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MULTIDRUG RESISTANCE; NUCLEIC ACID AMPLIFICATION; PROCEDURES; SPUTUM;

ANTITUBERCULAR AGENTS; DNA PROBES; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; ISONIAZID; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; NUCLEIC ACID AMPLIFICATION TECHNIQUES; RIFAMPIN; SENSITIVITY AND SPECIFICITY; SPUTUM; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY;

EID: 85021145552     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/13993003.01075-2016     Document Type: Review

References (117)

1. World Health Organization. Global Tuberculosis Report. Geneva, World Health Organization, 2016. Available from: http://www.who.int/tb/publications/global-report/en/
2. World Health Organization. Multidrug and Extensively Drug-resistant TB (M/XDR-TB): 2010 Global Report on Surveillance and Response. Geneva, World Health Organization, 2010. Available from: http://apps.who.int/iris/bitstream/10665/44286/1/9789241599191-eng.pdf
3. Heifets LB, Cangelosi GA. Drug susceptibility testing of Mycobacterium tuberculosis: a neglected problem at the turn of the century. Int J Tuberc Lung Dis 1999; 3: 564-581.
4. Dinnes J, Deeks J, Kunst H, et al. A systematic review of rapid diagnostic tests for the detection of tuberculosis infection. Health Technol Assess 2007; 11: 1-196.
5. Small PM, Pai M. Tuberculosis diagnosis: time for a game change. N Engl J Med 2010; 363: 1070-1071.
6. Ling DI, Zwerling AA, Pai M. Rapid diagnosis of drug-resistant TB using line probe assays: from evidence to policy. Expert Rev Respir Med 2008; 2: 583-588.
7. Telenti A, Honore N, Bernasconi C, et al. Genotypic assessment of isoniazid and rifampin resistance in Mycobacterium tuberculosis: a blind study at reference laboratory level. J Clin Microbiol 1997; 35: 719-723.
8. Mokrousov I, Narvskaya O, Otten T, et al. High prevalence of KatG Ser315Thr substitution among isoniazid-resistant Mycobacterium tuberculosis clinical isolates from northwestern Russia, 1996 to 2001. Antimicrob Agents Chemother 2002; 46: 1417-1424.
9. Musser JM, Kapur V, Williams DL, et al. Characterization of the catalase-peroxidase gene (katG) and inhA locus in isoniazid-resistant and -susceptible strains of Mycobacterium tuberculosis by automated DNA sequencing: restricted array of mutations associated with drug resistance. J Infect Dis 1996; 173: 196-202.
10. Seifert M, Catanzaro D, Catanzaro A, et al. Genetic mutations associated with isoniazid resistance in Mycobacterium tuberculosis: a systematic review. PLoS One 2015; 10: e0119628.
11. Sreevatsan S, Pan X, Zhang Y, et al. Analysis of the oxyR-ahpC region in isoniazid-resistant and -susceptible Mycobacterium tuberculosis complex organisms recovered from diseased humans and animals in diverse localities. Antimicrob Agents Chemother 1997; 41: 600-606.
12. World Health Organization. WHO policy statement. Molecular line probe assays for rapid screening of patients at risk of multidrug-resistant tuberculosis (English and Russian), 2008. www.who.int/tb/features-archive/policy-statement.pdf?ua=1 Date last accessed: December 22, 2016.
13. Ling DI, Zwerling AA, Pai M. GenoType MTBDR assays for the diagnosis of multidrug-resistant tuberculosis: a meta-analysis. Eur Respir J 2008; 32: 1165-1174.
14. Barnard M, Gey van Pittius NC, van Helden PD, et al. The diagnostic performance of the GenoType MTBDRplus version 2 line probe assay is equivalent to that of the Xpert MTB/RIF assay. J Clin Microbiol 2012; 50: 3712-3716.
15. Crudu V, Stratan E, Romancenco E, et al. First evaluation of an improved assay for molecular genetic detection of tuberculosis as well as rifampin and isoniazid resistances. J Clin Microbiol 2012; 50: 1264-1269.
16. Arentz M, Sorensen B, Horne DJ, et al. Systematic review of the performance of rapid rifampicin resistance testing for drug-resistant tuberculosis. PLoS One 2013; 8: e76533.
17. Mitarai S, Kato S, Ogata H, et al. Comprehensive multicenter evaluation of a new line probe assay kit for identification of Mycobacterium species and detection of drug-resistant Mycobacterium tuberculosis. J Clin Microbiol 2012; 50: 884-890.
18. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009; 6: e1000097.
19. Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy. The Cochrane Collaboration, London, 2008. http://methods.cochrane.org/sdt/handbook-dta-reviews Date last accessed: December 22, 2016.
20. Whiting PF, Rutjes AW, Westwood ME, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 2011; 155: 529-536.
21. Chu H, Cole SR. Bivariate meta-analysis of sensitivity and specificity with sparse data: a generalized linear mixed model approach. J Clin Epidemiol 2006; 59: 1331-1332.
22. Reitsma JB, Glas AS, Rutjes AW, et al. Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews. J Clin Epidemiol 2005; 58: 982-990.
23. Al-Mutairi NM, Ahmad S, Mokaddas E. Performance comparison of four methods for detecting multidrug-resistant Mycobacterium tuberculosis strains. Int J Tuberc Lung Dis 2011; 15: 110-115.
24. Albert H, Bwanga F, Mukkada S, et al. Rapid screening of MDR-TB using molecular line probe assay is feasible in Uganda. BMC Infect Dis 2010; 10: 41.
25. Anek-Vorapong R, Sinthuwattanawibool C, Podewils LJ, et al. Validation of the GenoType MTBDRplus assay for detection of MDR-TB in a public health laboratory in Thailand. BMC Infect Dis 2010; 10: 123.
26. Asante-Poku A, Otchere ID, Danso E, et al. Evaluation of GenoType MTBDRplus for the rapid detection of drug-resistant tuberculosis in Ghana. Int J Tuberc Lung Dis 2015; 19: 954-959.
27. Asencios L, Galarza M, Quispe N, et al. Molecular test GenotypeMTBDRplus, an alternative to rapid detection of multidrug resistance tuberculosis. Revista Peruana de Medicina Experimental y Salud Publica 2012; 29: 92-98.
28. Aung WW, Ei PW, Nyunt WW, et al. Phenotypic and genotypic analysis of anti-tuberculosis drug resistance in Mycobacterium tuberculosis isolates in Myanmar. Ann Lab Med 2015; 35: 494-499.
29. Aurin TH, Munshi SK, Kamal SM, et al. Molecular approaches for detection of the multi-drug resistant tuberculosis (MDR-TB) in Bangladesh. PloS One 2014; 9: e99810.
30. Bablishvili N, Tukvadze N, Avaliani Z, et al. A comparison of the Xpert MTB/RIF and GenoType MTBDRplus assays in Georgia. Int J Tuberc Lung Dis 2015; 19: 676-678.
31. Banu S, Rahman SMM, Khan MSR, et al. Discordance across several methods for drug susceptibility testing of drug-resistant Mycobacterium tuberculosis isolates in a single laboratory. J Clin Microbiol 2014; 52: 156-163.
32. Barnard M, Albert H, Coetzee G, et al. Rapid molecular screening for multidrug-resistant tuberculosis in a high-volume public health laboratory in South Africa. Am J Respir Crit Care Med 2008; 177: 787-792.
33. Brossier F, Veziris N, Jarlier V, et al. Performance of MTBDR plus for detecting high/low levels of Mycobacterium tuberculosis resistance to isoniazid. Int J Tuberc Lung Dis 2009; 13: 260-265.
34. Bwanga F, Joloba ML, Haile M, et al. Evaluation of seven tests for the rapid detection of multidrug-resistant tuberculosis in Uganda. Int J Tuberc Lung Dis 2010; 14: 890-895.
35. Cabibbe AM, Miotto P, Moure R, et al. A lab-on-chip based platform for fast molecular diagnosis of multi-drug resistant tuberculosis. J Clin Microbiol 2015.
36. Catanzaro A, Rodwell TC, Catanzaro DG, et al. Performance comparison of three rapid tests for the diagnosis of drug-resistant tuberculosis. PLoS One 2015; 10: e0136861.
37. Causse M, Ruiz P, Gutierrez JB, et al. Evaluation of new GenoType MTBDRplus for detection of resistance in cultures and direct specimens of Mycobacterium tuberculosis. Int J Tuberc Lung Dis 2008; 12: 1456-1460.
38. Chen C, Kong W, Zhu L, et al. Evaluation of the GenoType MTBDRplus line probe assay on sputum-positive samples in routine settings in China. Int J Tuberc Lung Dis 2014; 18: 1034-1039.
39. Chryssanthou E, Angeby K. The GenoType MTBDRplus assay for detection of drug resistance in Mycobacterium tuberculosis in Sweden. APMIS 2012; 120: 405-409.
40. Daum LT, Rodriguez JD, Worthy SA, et al. Next-generation ion torrent sequencing of drug resistance mutations in Mycobacterium tuberculosis strains. J Clin Microbiol 2012; 50: 3831-3837.
41. Dorman SE, Chihota VN, Lewis JJ, et al. Genotype MTBDRplus for direct detection of Mycobacterium tuberculosis and drug resistance in strains from gold miners in South Africa. J Clin Microbiol 2012; 50: 1189-1194.
42. Dubois Cauwelaert N, Ramarokoto H, et al. DNA extracted from stained sputum smears can be used in the MTBDRplus assay. J Clin Microbiol 2011; 49: 3600-3603.
43. Eliseev PI, Maryandyshev AO, Nikishova EI, et al. Epidemiological analyses of tuberculosis in Archangelsk, Russia and implementation of a rapid assay for detection of resistance in this high burden setting. Int J Mycobacteriol 2013; 2: 103-108.
44. Evans J, Stead MC, Nicol MP, et al. Rapid genotypic assays to identify drug-resistant Mycobacterium tuberculosis in South Africa. J Antimicrob Chemother 2009; 63: 11-16.
45. Fabre M, Hauck Y, Pourcel C, et al. Performances of the assay MTBDRplus in the surveillance of rifampicin resistance in Mycobacterium tuberculosis. Pathologie Biologie 2011; 59: 94-96.
46. Farooqi JQ, Khan E, Alam SM, et al. Line probe assay for detection of rifampicin and isoniazid resistant tuberculosis in Pakistan. J Pak Med Assoc 2012; 62: 767-772.
47. Felkel M, Exner R, Schleucher R, et al. Evaluation of Mycobacterium tuberculosis drug susceptibility in clinical specimens from Nigeria using genotype MTBDRplus and MTBDRsl assays. Eur J Microbiol Immunol (Bp) 2013; 3: 252-257.
48. Ferro BE, Garcia PK, Nieto LM, et al. Predictive value of molecular drug resistance testing of Mycobacterium tuberculosis isolates in Valle del Cauca, Colombia. J Clin Microbiol 2013; 51: 2220-2224.
49. Friedrich SO, Venter A, Kayigire XA, et al. Suitability of Xpert MTB/RIF and genotype MTBDRplus for patient selection for a tuberculosis clinical trial. J Clin Microbiol 2011; 49: 2827-2831.
50. Gauthier M, Somoskovi A, Berland JL, et al. Stepwise implementation of a new diagnostic algorithm for multidrug-resistant tuberculosis in Haiti. Int J Tuberc Lung Dis 2014; 18: 220-226.
51. Gitti Z, Mantadakis E, Maraki S, et al. GenoType(R) MTBDRplus compared with conventional drug-susceptibility testing of Mycobacterium tuberculosis in a low-resistance locale. Future Microbiol 2011; 6: 357-362.
52. Hillemann D, Rusch-Gerdes S, Richter E. Evaluation of the GenoType MTBDRplus assay for rifampin and isoniazid susceptibility testing of Mycobacterium tuberculosis strains and clinical specimens. J Clin Microbiol 2007; 45: 2635-2640.
53. Huang FL, Jin JL, Chen S, et al. MTBDRplus results correlate with treatment outcome in previously treated tuberculosis patients. Int J Tuberc Lung Dis 2015; 19: 319-325.
54. Huang WL, Chen HY, Kuo YM, et al. Performance assessment of the GenoType MTBDRplus test and DNA sequencing in detection of multidrug-resistant Mycobacterium tuberculosis. J Clin Microbiol 2009; 47: 2520-2524.
55. Huang WL, Hsu ZJ, Chang TC, et al. Rapid and accurate detection of rifampin and isoniazid-resistant Mycobacterium tuberculosis using an oligonucleotide array. Clin Microbiol Infect 2014; 20: O542-O549.
56. Huyen MN, Tiemersma EW, Lan NT, et al. Validation of the GenoType MTBDRplus assay for diagnosis of multidrug resistant tuberculosis in South Vietnam. BMC Infect Dis 2010; 10: 149.
57. Imperiale BR, Zumarraga MJ, Weltman G, et al. First evaluation in Argentina of the GenoType MTBDRplus assay for multidrug-resistant Mycobacterium tuberculosis detection from clinical isolates and specimens. Rev Argent Microbiol 2012; 44: 283-289.
58. Jin J, Zhang Y, Fan X, et al. Evaluation of the GenoType MTBDRplus assay and identification of a rare mutation for improving MDR-TB detection. Int J Tuberc Lung Dis 2012; 16: 521-526.
59. Kapata N, Mbulo G, Cobelens F, et al. The Second Zambian National Tuberculosis Drug Resistance survey: a comparison of conventional and molecular methods. Trop Med Int Health 2015; 20: 1492-1500.
60. Khadka JB, Rai SK, Shrestha S, et al. Study of rifampicin and isoniazid resistance mutation genes of M. tuberculosis isolates in Nepal. Nepal Med Coll J 2011; 13: 147-151.
61. Kumar P, Balooni V, Sharma BK, et al. High degree of multi-drug resistance and hetero-resistance in pulmonary TB patients from Punjab state of India. Tuberculosis (Edinb) 2014; 94: 73-80.
62. Lacoma A, Garcia-Sierra N, Prat C, et al. GenoType MTBDRplus assay for molecular detection of rifampin and isoniazid resistance in Mycobacterium tuberculosis strains and clinical samples. J Clin Microbiol 2008; 46: 3660-3667.
63. Li Q, Dong HY, Pang Y, et al. Multicenter evaluation of the molecular line probe assay for multidrug resistant Mycobacterium tuberculosis detection in China. Biomed Environ Sci 2015; 28: 464-467.
64. Luetkemeyer AF, Kendall MA, Wu X, et al. Evaluation of two line probe assays for rapid detection of Mycobacterium tuberculosis, tuberculosis (TB) drug resistance, and non-TB Mycobacteria in HIV-infected individuals with suspected TB. J Clin Microbiol 2014; 52: 1052-1059.
65. Lyu J, Kim MN, Song JW, et al. GenoType MTBDRplus assay detection of drug-resistant tuberculosis in routine practice in Korea. Int J Tuberc Lung Dis 2013; 17: 120-124.
66. Macedo R, Amorim A, Pereira E. Multidrug-resistant tuberculosis: rapid molecular detection with MTBDRplus assay in clinical samples. Rev Port Pneumol 2009; 15: 353-365.
67. Maschmann Rde A, Sa Spies F, Nunes, et al. Performance of the GenoType MTBDRplus assay directly on sputum specimens from Brazilian patients with tuberculosis treatment failure or relapse. J Clin Microbiol 2013; 51: 1606-1608.
68. Miotto P, Piana F, Cirillo DM, et al. Genotype MTBDRplus: a further step toward rapid identification of drug-resistant Mycobacterium tuberculosis. J Clin Microbiol 2008; 46: 393-394.
69. Miotto P, Saleri N, Dembele M, et al. Molecular detection of rifampin and isoniazid resistance to guide chronic TB patient management in Burkina Faso. BMC Infect Dis 2009; 9: 142.
70. Mironova S, Pimkina E, Kontsevaya I, et al. Performance of the GenoType MTBDRPlus assay in routine settings: a multicenter study. Eur J Clin Microbiol Infect Dis 2012; 31: 1381-1387.
71. N'Guessan K, Assi JS, Ouassa T, et al. Assessment of the GenoType MTBDRplus assay for rifampin and isoniazid resistance detection on sputum samples in Cote d'Ivoire. Eur J Microbiol Immunol (Bp) 2014; 4: 166-173.
72. Nathavitharana RR, Hillemann D, Schumacher SG, et al. Multicenter noninferiority evaluation of Hain GenoType MTBDRplus Version 2 and Nipro NTM+MDRTB line probe assays for detection of rifampin and isoniazid resistance. J Clin Microbiol 2016; 54: 1624-1630.
73. Niehaus AJ, Mlisana K, Gandhi NR, et al. High prevalence of inhA promoter mutations among patients with drug-resistant tuberculosis in KwaZulu-Natal, South Africa. PLoS One 2015; 10: e0135003.
74. Nikolayevskyy V, Balabanova Y, Simak T, et al. Performance of the Genotype MTBDRPlus assay in the diagnosis of tuberculosis and drug resistance in Samara, Russian Federation. BMC Clin Pathol 2009; 9: 2.
75. Nwofor AC, Nyamngee A, Nwabuisi C, et al. Performance of Genotype MTBDRplus in the detection of resistance to rifampicin and isoniazid among clinical mycobacteria isolates in Ilorin, Nigeria. Curr HIV Res 2015; 13: 308-314.
76. Ocheretina O, Escuyer VE, Mabou MM, et al. Correlation between genotypic and phenotypic testing for resistance to rifampin in Mycobacterium tuberculosis clinical isolates in Haiti. Investigation of cases with discrepant susceptibility results. Plos One 2014; 9: e90569.
77. Raizada N, Sachdeva KS, Chauhan DS, et al. A multi-site validation in India of the line probe assay for the rapid diagnosis of multi-drug resistant tuberculosis directly from sputum specimens. PLoS One 2014; 9: e88626.
78. Raveendran R, Wattal C, Oberoi JK, et al. Utility of GenoType MTBDRplus assay in rapid diagnosis of multidrug resistant tuberculosis at a tertiary care centre in India. Indian J Med Microbiol 2012; 30: 58-63.
79. Rienthong S, Boonin C, Chaiyasirinrote B, et al. Evaluation of a novel line-probe assay for genotyping-based diagnosis of Mycobacterium tuberculosis in Thailand. Int J Tuberc Lung Dis 2015; 19: 817-822.
80. Rigouts L, Hoza AS, De Rijk P, et al. Evaluation of the Genotype MTBDRplus assay as a tool for drug resistance surveys. Int J Tuberc Lung Dis 2011; 15: 959-965.
81. Rufai SB, Kumar P, Singh A, et al. Comparison of Xpert MTB/RIF with line probe assay for detection of rifampin-monoresistant Mycobacterium tuberculosis. J Clin Microbiol 2014; 52: 1846-1852.
82. Sangsayunh P, Chuchothawon C. Genotype MTBDR plus (Hain) test in suspected MDR-TB patients. J Med Assoc Thai 2014; 97: 1028-1032.
83. Schon T, Jureen P, Chryssanthou E, et al. Rifampicin-resistant and rifabutin-susceptible Mycobacterium tuberculosis strains: a breakpoint artefact? J Antimicrob Chemother 2013; 68: 2074-2077.
84. Scott LE, McCarthy K, Gous N, et al. Comparison of Xpert MTB/RIF with other nucleic acid technologies for diagnosing pulmonary tuberculosis in a high HIV prevalence setting: a prospective study. PLoS Med 2011; 8: e1001061.
85. Shubladze N, Tadumadze N, Bablishvili N. Molecular patterns of multidrug resistance of in Georgia. Int J Mycobacteriol 2013; 2: 73-78.
86. Simons SO, van der Laan T, de Zwaan R, et al. Molecular drug susceptibility testing in the Netherlands: performance of the MTBDRplus and MTBDRsl assays. Int J Tuberc Lung Dis 2015; 19: 828-833.
87. Singhal R, Arora J, Lal P, et al. Comparison of line probe assay with liquid culture for rapid detection of multi-drug resistance in Mycobacterium tuberculosis. Indian J Med Res 2012; 136: 1044-1047.
88. Tessema B, Beer J, Emmrich F, et al. Analysis of gene mutations associated with isoniazid, rifampicin and ethambutol resistance among Mycobacterium tuberculosis isolates from Ethiopia. BMC Infect Dis 2012; 12: 37.
89. Tho DQ, Lan NT, Chau NV, et al. Multiplex allele-specific polymerase chain reaction for detection of isoniazid resistance in Mycobacterium tuberculosis. Int J Tuberc Lung Dis 2011; 15: 799-803.
90. Tolani MP, D'Souza DT, Mistry NF. Drug resistance mutations and heteroresistance detected using the GenoType MTBDRplus assay and their implication for treatment outcomes in patients from Mumbai, India. BMC Infect Dis 2012; 12: 9.
91. Tukvadze N, Kempker RR, Kalandadze I, et al. Use of a molecular diagnostic test in AFB smear positive tuberculosis suspects greatly reduces time to detection of multidrug resistant tuberculosis. PLoS One 2012; 7: e31563.
92. Vijdea R, Stegger M, Sosnovskaja A, et al. Multidrug-resistant tuberculosis: rapid detection of resistance to rifampin and high or low levels of isoniazid in clinical specimens and isolates. Eur J Clin Microbiol Infect Dis 2008; 27: 1079-1086.
93. Yadav RN, Singh BK, Sharma SK, et al. Comparative evaluation of GenoType MTBDRplus line probe assay with solid culture method in early diagnosis of multidrug resistant tuberculosis (MDR-TB) at a tertiary care centre in India. PLoS One 2013; 8: e72036.
94. Yordanova S, Bachiyska E, Atanasova Y, et al. Multidrug resistant tuberculosis in Bulgaria-atmicrobiological aspects|. Probl Infect Parasit Dis 2013; 41: 5-8.
95. Smith SE, Kurbatova EV, Cavanaugh JS, et al. Global isoniazid resistance patterns in rifampin-resistant and rifampin-susceptible tuberculosis. Int J Tuberc Lung Dis 2012; 16: 203-205.
96. Steingart KR, Schiller I, Horne DJ, et al. Xpert MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database Syst Rev 2014; 1: CD009593.
97. Gillespie SH. Evolution of drug resistance in Mycobacterium tuberculosis: clinical and molecular perspective. Antimicrob Agents Chemother 2002; 46: 267-274.
98. Muller B, Borrell S, Rose G, et al. The heterogeneous evolution of multidrug-resistant Mycobacterium tuberculosis. Trends Genet 2013; 29: 160-169.
99. Sanchez-Padilla E, Merker M, Beckert P, et al. Detection of drug-resistant tuberculosis by Xpert MTB/RIF in Swaziland. N Engl J Med 2015; 372: 1181-1182.
100. Van Deun A, Aung KJ, Bola V, et al. Rifampin drug resistance tests for tuberculosis: challenging the gold standard. J Clin Microbiol 2013; 51: 2633-2640.
101. Van Deun A, Aung KJ, Hossain A, et al. Disputed rpoB mutations can frequently cause important rifampicin resistance among new tuberculosis patients. Int J Tuberc Lung Dis 2015; 19: 185-190.
102. Bossuyt PM, Reitsma JB, Bruns DE, et al. STARD 2015: an updated list of essential items for reporting diagnostic accuracy studies. BMJ 2015; 351: h5527.
103. Fontela PS, Pant Pai N, Schiller I, et al. Quality and reporting of diagnostic accuracy studies in TB, HIV and malaria: evaluation using QUADAS and STARD standards. PLoS One 2009; 4: e7753-e7700.
104. Uplekar M, Weil D, Lonnroth K, et al. WHO's new end TB strategy. Lancet 2015; 385: 1799-1801.
105. TB CARE I. International Standards for Tuberculosis Care. 3rd Edn. The Hague, TB CARE I, 2014.
106. Lonnroth K, Migliori GB, Abubakar I, et al. Towards tuberculosis elimination: an action framework for low-incidence countries. Eur Respir J 2015; 45: 928-952.
107. Rendon A, Fuentes Z, Torres-Duque CA, et al. Roadmap for tuberculosis elimination in Latin American and Caribbean countries: a strategic alliance. Eur Respir J 2016; 48: 1282-1287.
108. D'Ambrosio L, Dara M, Tadolini M, et al. Tuberculosis elimination: theory and practice in Europe. Eur Respir J 2014; 43: 1410-1420.
109. Van Deun A, Maug AK, Salim MA, et al. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med 2010; 182: 684-692.
110. World Health Organization. WHO treatment guidelines for drug-resistant tuberculosis. 2016 update WHO/HTM/TB/2016.04. World Health Organization, Geneva, 2016. Available from: www.who.int/tb/MDRTBguidelines2016.pdf
111. Caminero JA, Sotgiu G, Zumla A, et al. Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis. Lancet Infect Dis 2010; 10: 621-629.
112. Jacobson KR, Theron D, Victor TC, et al. Treatment outcomes of isoniazid-resistant tuberculosis patients, Western Cape Province, South Africa. Clin Infect 2011; 53: 369-372.
113. Vilcheze C, Jacobs WR Jr. The mechanism of isoniazid killing: clarity through the scope of genetics. Annu Rev Microbiol 2007; 61: 35-50.
114. Warren RM, Streicher EM, Gey van Pittius NC, et al. The clinical relevance of Mycobacterial pharmacogenetics. Tuberculosis (Edinb) 2009; 89: 199-202.
115. High-Dose Isoniazid Among Adult Patients With Different Genetic Variants of INH-Resistant Tuberculosis (TB). https://clinicaltrials.gov/ct2/show/NCT0193683. Date last accessed August 25, 2016.
116. Sotgiu G, Tiberi S, D'Ambrosio L, et al. Faster for less, the new 'Shorter' regimen for multidrug-resistant tuberculosis. Eur Respir J 2016; 48: 1503-1507.
117. Sotgiu G, Tiberi S, D'Ambrosio L, et al. WHO recommendations on shorter treatment of multidrug-resistant tuberculosis. Lancet 2016; 387: 2486-2487.